{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine SBP - Value <90 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Supine SBP - Change ≥ 30 mmHg Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine SBP - Change ≥ 30 mmHg Decrease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine DBP - Value <50 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Supine DBP - Change ≥ 20 mmHg Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine DBP - Change ≥ 20 mmHg Decrease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine Pulse Rate - Value <40 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine Pulse Rate - Value >120 bpm"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) \\<90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline ≥30 mmHg; supine diastolic blood pressure (DBP) \\<50 mmHg, supine DBP increase/decrease from baseline ≥20 mmHg; supine pulse rate \\<40 beats per minute (bpm) or \\>120 bpm.","groups":[{"description":"During the 12-week treatment period, participants receive a total of 5 SC doses of PF-06946860 Q3W.","id":"OG000","title":"PF-06946860 Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Overall number of participants analyzed included participants evaluated against pre-defined criteria for vital signs.","reportingStatus":"POSTED","timeFrame":"From Day 1 up to Week 24","title":"Number of Participants With Post-Baseline Vital Signs Abnormalities","type":"PRIMARY","unitOfMeasure":"Participants"}